SENSING TECHNOLOGY

OPTO CIRCUITS (INDIA) LIMITED. (UNIT II) 100% EOU

OPTO CIRCUITS (INDIA) LTD.

December 6th 2010

THE NATIONAL STOCK EXCHANGE
EXCHANGE PLAZA
BANDRA KURLA COMPLEX
BANDRA [E]
MUMBAI - 400 051.

Dear Sir,

We would like to inform you that the Company's wholly-owned subsidiary, Eurocor GmbH, has received registration from Drug Controller General of India (DCGI) for its PTCA (Percutaneous Transluminal Coronary Angioplasty) Drug-Coated Stent delivery Balloon, MAGICAL™. The procedure using MAGICAL™ involves the introduction of a drug (paclitaxel) coated balloon into the target coronary vessel, release of the drug on balloon inflation and deployment of a cobalt chromium bare metal stent to keep the vessel open. This is a drug involving combination device (DEB; Drug Eluting Balloon + BMS; Bare Metal Stent) to have entered the Indian market that treats coronary indications with a stent and a balloon, with an objective to effectively deter the occurrence of restenosis and late stent thrombosis, two perilous risks associated with regular angioplasty treatments.

We are enclosing herewith the press release in this regard.

Thanking you,

Yours faithfully.
for OPTO CIRCUITS (INDIA) LTD.,

Authorised Signatory.

Plot No. 83, First Floor, Electronics City, Bangalore - 560 100.
Phone : +91-80-28521040-41-42 Fax : +91-80-28521094

Opto Circuits (India) Limited

Eurocor

Opto Circuits' subsidiary enters Indian market with PTCA combination device
- Company gets DCGI registration for "MAGICAL™" -

December 6, 2010 | Bengaluru, India | Bonn, Germany

Opto Circuits (India) Limited's wholly-owned subsidiary, Eurocor GmbH, has received registration from Drug Controller General of India (DCGI) for its PTCA (Percutaneous Transluminal Coronary Angioplasty) Drug-Coated Stent delivery Balloon, MAGICAL™. The procedure using MAGICAL™ involves the introduction of a drug (paclitaxel) coated balloon into the target coronary vessel, release of the drug on balloon inflation and deployment of a cobalt chromium bare metal stent to keep the vessel open. This is a drug involving combination device (DEB; Drug Eluting Balloon + BMS; Bare Metal Stent) to have entered the Indian market that treats coronary indications with a stent and a balloon, with an objective to effectively deter the occurrence of restenosis and late stent thrombosis, two perilous risks associated with regular angioplasty treatments.

MAGICAL™ is ideal for "High Risk Patients", who may have to face a surgical operation and for "Non-Compliant Patients" those, who do not follow the prescription of a physician. The greatest clinical advantage is limited need for anti-platelet therapy post treatment which provides better life quality after stenting.

Coronary Angioplasty (PTCA) is a widely used method of treating patients with blocked arteries. Until recently the most recurring problem for the long-term durability of angioplasty was restenosis (Re-Closure of the affected artery). Drug-Eluting Stents (DES) and Drug-Eluting Balloons (DEB) have markedly minimized this situation of restenosis, however DES may be susceptible to an event known as "late stent thrombosis", where the blood-clotting inside the stent can occur one or more years post-stenting. MAGICAL™ stenting eliminates the risk of late stent thrombosis as there is no synthetic polymer coating on the stent. There is no long-term drug associated late adverse effect potential.

MAGICAL™ – The Paclitaxel delivery Cobalt Chromium stent system provides the thinnest stent strut design (0.0025") for rapid healing. This is an option to significantly enhance the long-term quality of patient treatment. While the MAGICAL™ stent is expanded and deployed into the arterial wall at the lesion site, the stent delivery balloon is kept inside the expanded stent, inflated up to one minute for an optimal drug release to the coronary artery lesion. Paclitaxel is absorbed by the arterial wall at the lesion site.

About: Eurocor GmbH
Eurocor GmbH is a Bonn (Germany) based rapidly growing life sciences company specializing in the research and development of cardiovascular catheter products and coronary stent technologies. Eurocor's products are used in minimally invasive cardiovascular surgery and comply with biological and biochemical principles to offer highly-flexible, adaptive solutions. Eurocor GmbH is a wholly-owned subsidiary of Opto Circuits India.
For further details, please go to www.eurocor.de.

About: Opto Circuits (India) Ltd.
Opto Circuits (India) Ltd. (OCI) (BSE Code: 532391; NSE Symbol: OPTOCIRCUI), headquartered in Bengaluru, Karnataka, India, is a multi-national corporation in the business of design, development, manufacturing and marketing of non-invasive healthcare equipment and invasive vascular products. The product profile includes patient monitoring systems, anaesthesia and respiratory care equipment, pulse oximeters, sensors, stents, catheters and balloons. The Group has a consolidated turnover of Rs.1077 crores (FY2010). The company's key markets are in the US, Europe and Asia. OCI was ranked as one amongst 200 Best Under a Billion companies in Asia-Pacific by Forbes Asia in 2009 and 2008. For further details, please go to www.optoindia.com.

Contact: Media – media@optoindia.com | Investors – ir@optoindia.com | +91 80 2852 8088